Anna Chen

Anna joined Frazier Life Sciences in 2018, where she focuses on private investments and company creation. She co-led Frazier’s investments in and currently serves on the boards of Eyconis and Blue Water Bio. She is currently a board observer at Inipharm, Attovia Therapeutics, Architect Therapeutics, and Diagonal Therapeutics. Anna has also been involved in Frazier’s investments in Amunix Pharmaceuticals (acquired by Sanofi), Lengo Therapeutics (acquired by Blueprint Medicines), SanReno Therapeutics (acquired by Novartis), and HilleVax (NASDAQ: HLVX).

Prior to joining Frazier, Anna was a management consultant in L.E.K. Consulting’s life sciences practice. While at L.E.K., Anna advised leading biotechnology and pharmaceutical companies on strategic planning, organizational development, R&D, and business development strategy. Previously, Anna was an entrepreneurial fellow at Flagship Pioneering and a business mentor for the National Science Foundation Innovation Corps program. In addition, she has been involved in startup incubation of several projects from academic labs, including a targeted drug delivery device and a single molecule protein sequencing technology.

Anna received her Ph.D. in Systems Biology from Harvard University, where she was a National Science Foundation Graduate Research Fellow. Her research resulted in numerous publications in peer-reviewed journals, including Science and PLOS. Anna also holds an A.B. in Biochemical Sciences from Harvard College.